BCR(KLHL9-KLHL13) E3 Ubiquitin Ligase Complex Regulates TCR, Gene Expression and Cell Growth

Target Name: BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex

NCBI ID: P38466

BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex

Other Name(s): None

BCR(KLHL9-KLHL13) E3 Ubiquitin Ligase Complex Regulates TCR, Gene Expression and Cell Growth

The BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex is a protein complex that plays a crucial role in the regulation of gene expression and cell signaling. The BCR gene is a member of the Bcr/Abl gene family, which is known for their ability to induce leukemia in humans. The KLHL9 gene is a non-coding RNA gene that is expressed in a variety of tissues and is involved in the regulation of cell growth and differentiation. The E3 ubiquitin ligase complex is a protein complex that consists of three subunits: BCL3, KLHL9, and E1A. This complex plays a critical role in the regulation of gene expression by ubiquitinating target proteins and regulating their stability.

The BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex is a complex that consists of three subunits: BCL3, KLHL9, and E1A. BCL3 is a protein that contains a N-terminal ubiquitin-like domain and a C-terminal T-cell receptor (TCR) domain. BCL3 functions as a negative regulator of the TCR, which is a protein that plays a critical role in cell signaling. KLHL9 is a non-coding RNA gene that is expressed in a variety of tissues and is involved in the regulation of cell growth and differentiation. E1A is a protein that contains a N-terminal ubiquitin-like domain and a C-terminal T-cell receptor (TCR) domain. E1A functions as a positive regulator of the TCR, which is a protein that plays a critical role in cell signaling.

The BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex functions as a negative regulator of the TCR. This means that when the TCR is activated, the BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex will ubiquitinate the TCR, which will in turn inhibit its ability to function as a signaling molecule. This regulation is important for the control of cell signaling and the regulation of cell growth and differentiation.

The BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex is also involved in the regulation of gene expression. This is done by the BCL3 protein, which contains a N-terminal ubiquitin-like domain and a C-terminal T-cell receptor (TCR) domain. BCL3 functions as a negative regulator of the TCR, which means that when the TCR is activated, BCL3 will ubiquitinate the TCR, which will in turn inhibit its ability to function as a signaling molecule. This regulation is important for the control of gene expression and the regulation of cell signaling.

The BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex is also involved in the regulation of cell growth and differentiation. This is done by the KLHL9 protein, which is a non-coding RNA gene that is expressed in a variety of tissues and is involved in the regulation of cell growth and differentiation. KLHL9 functions as a negative regulator of the TCR, which means that when the TCR is activated, KLHL9 will ubiquitinate the TCR, which will in turn inhibit its ability to function as a signaling molecule. This regulation is important for the control of cell growth and differentiation.

In conclusion, the BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex is a protein complex that plays a critical role in the regulation of gene expression, cell signaling, and cell growth and differentiation. The BCL3, KLHL9, and E1A proteins that make up the BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex are involved in the regulation of

Protein Name: BCR(KLHL9-KLHL13) E3 Ubiquitin Ligase Complex

The "BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets